Lab Genomics

The firm invests in early-stage AI and biotechnology startups whose models benefit from access to labeled, population-specific genomic datasets. Lab Genomics uses its proprietary East Asian bio-bank, maintained in South Korea, to both source and diligence deals that would be difficult for a purely US-based fund to evaluate. The thesis targets a valuation gap between data-rich precision medicine companies and the capital markets' slower recognition of biodata as a durable competitive asset.

Sourcing is built around the bio-repository in Seongnam. Academic collaborators at Korean university hospitals refer startups seeking validation cohorts, while the Foster City office converts Bay Area founders who need access to Asian phenotypic data for clinical trials or algorithm training. The firm also scans the commercial sequencing ecosystem in Asia for infrastructure plays that sit upstream of the data-generation curve.

Lab Genomics makes direct equity investments and also structures data-licensing arrangements where the bio-bank is contributed as in-kind value. The firm has not publicly disclosed any fund-of-funds commitments, operating instead as a direct investor at the Seed through Series B stages in biotechnology and digital health.

The firm does not invest in therapeutics companies that require expensive, multi-year FDA clinical trials outside its data partnerships. It also avoids direct-to-consumer genetic testing models with unproven reimbursement pathways. The focus remains on the picks-and-shovels layer of genomic computation rather than long-duration drug development or retail health apps.

No philanthropic foundation or separate research entity has been disclosed. The bio-bank and associated research activities appear to sit within the same corporate structure as the venture operations, though the firm's collaborative agreements with hospital systems include their own institutional review and consent governance.

Lab Genomics participates in syndicated rounds, typically contributing data rights alongside cash from lead investors. The firm will accept a board observation seat rather than a full directorship, integrating its data-platform team into the portfolio company's scientific advisory arrangements. This posture makes Lab Genomics a complementary co-investor for life-science VCs that lack their own Asian genomic datasets.

The firm maintains research collaboration agreements with several university-hospital systems in the Seoul metropolitan area, with the bio-bank drawing longitudinal samples and phenotypic data from these institutions under formal data-governance protocols. Lab Genomics is not a subsidiary of or controlled by any single hospital, operating as an independent venture platform that licenses data access in exchange for shared research capabilities.